ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio

ResMed Inc. (NYSE:RMD) is one of the most undervalued large cap stocks to buy according to analysts. On June 1, ResMed finalized its acquisition of Noctrix Health, a medical device company known for developing non-pharmacologic wearable therapeutics. This strategic move expands ResMed’s clinical sleep health portfolio into the treatment of Restless Legs Syndrome/RLS, which is the third most prevalent sleep disorder globally.

The centerpiece of the acquisition is the Nidra Tonic Motor Activation/TOMAC Therapy. This FDA De Novo classified, non-invasive device is specifically designed to reduce symptoms in adults with moderate-to-severe RLS who have not achieved sufficient relief through traditional drug therapies. The technology is backed by robust clinical validation, including inclusion in American Academy of Sleep Medicine/AASM guidelines.

ResMed Inc. (NYSE:RMD) plans to integrate this technology into its existing ecosystem of connected devices and digital health solutions to improve patient access and care pathways. Following the completion of the deal, Noctrix Health now operates as a wholly owned subsidiary of ResMed, supporting the company’s broader 2030 strategy to advance home-based sleep and respiratory care.

ResMed Inc. (NYSE:RMD) develops and manufactures medical devices and digital health solutions for sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions. Its products include CPAP machines, masks, and cloud-connected software platforms that enable remote patient monitoring and management.

While we acknowledge the risk and potential of RMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RMD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1